Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia.

Wang, Feng; Morita, Kiyomi; DiNardo, Courtney D; Furudate, Ken; Tanaka, Tomoyuki; Yan, Yuanqing; Patel, Keyur P; MacBeth, Kyle J; Wu, Bin; Liu, Guowen; Frattini, Mark; Matthews, Jairo A; Little, Latasha D; Gumbs, Curtis; Song, Xingzhi; Zhang, Jianhua; Thompson, Erika J; Kadia, Tapan M; Garcia-Manero, Guillermo; Jabbour, Elias; Ravandi, Farhad; Bhalla, Kapil N; Konopleva, Marina; Kantarjian, Hagop M; Andrew Futreal, P; Takahashi, Koichi

Wang, Feng; Morita, Kiyomi; DiNardo, Courtney D; Furudate, Ken; Tanaka, Tomoyuki; Yan, Yuanqing; Patel, Keyur P; MacBeth, Kyle J; Wu, Bin; Liu, Guowen; Frattini, Mark; Matthews, Jairo A; Little, Latasha D; Gumbs, Curtis; Song, Xingzhi; Zhang, Jianhua; Thompson, Erika J; Kadia, Tapan M; Garcia-Manero, Guillermo; Jabbour, Elias; Ravandi, Farhad; Bhalla, Kapil N; Konopleva, Marina; Kantarjian, Hagop M; Andrew Futreal, P; Takahashi, Koichi.

Afiliação

Wang F; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Morita K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
DiNardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. cdinardo@mdanderson.org.
Furudate K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Tanaka T; Department of Oral and Maxillofacial Surgery, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan.
Yan Y; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Patel KP; Department of Neurosurgery, The University of Texas Health Science Center at Houston, Houstont, TX, USA.
MacBeth KJ; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Wu B; Celgene Corporation, Summit, NJ, USA.
Liu G; Agios Pharmaceuticals, Cambridge, MA, USA.
Frattini M; Agios Pharmaceuticals, Cambridge, MA, USA.
Matthews JA; Celgene Corporation, Summit, NJ, USA.
Little LD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Gumbs C; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Song X; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Zhang J; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Thompson EJ; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kadia TM; Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jabbour E; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Bhalla KN; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Konopleva M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Andrew Futreal P; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Takahashi K; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. afutreal@mdanderson.org.

Nat Commun ; 12(1): 2607, 2021 05 10.

Article em En | MEDLINE | ID: mdl-33972549

Assuntos

Antineoplásicos/uso terapêutico; Metilação de DNA; Resistencia a Medicamentos Antineoplásicos/genética; Inibidores Enzimáticos/uso terapêutico; Isocitrato Desidrogenase/antagonistas & inibidores; Leucemia Mieloide Aguda/tratamento farmacológico; Recidiva Local de Neoplasia/genética; Células-Tronco/metabolismo; Idoso; Aminopiridinas/uso terapêutico; Proteínas Estimuladoras de Ligação a CCAAT/genética; Subunidade alfa 2 de Fator de Ligação ao Core/genética; Metilação de DNA/efeitos dos fármacos; Metilação de DNA/genética; Proteínas de Ligação a DNA/genética; Dioxigenases; Epigenômica; Evolução Molecular; Feminino; Glicina/análogos & derivados; Glicina/uso terapêutico; Sequenciamento de Nucleotídeos em Larga Escala; Humanos; Isocitrato Desidrogenase/genética; Leucemia Mieloide Aguda/genética; Leucemia Mieloide Aguda/metabolismo; Leucemia Mieloide Aguda/patologia; Masculino; Pessoa de Meia-Idade; Família Multigênica; Recidiva Local de Neoplasia/tratamento farmacológico; Proteínas Proto-Oncogênicas/genética; Piridinas/uso terapêutico; RNA-Seq; Proteínas Repressoras/genética; Transdução de Sinais/efeitos dos fármacos; Transdução de Sinais/genética; Análise de Célula Única; Triazinas/uso terapêutico; Proteínas ras/genética

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Células-Tronco / Leucemia Mieloide Aguda / Resistencia a Medicamentos Antineoplásicos / Metilação de DNA / Inibidores Enzimáticos / Isocitrato Desidrogenase / Recidiva Local de Neoplasia / Antineoplásicos Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Reino Unido

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google